The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals

August 23, 2011 updated by: Zealand University Hospital

The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals. A Randomised Double Blinded Placebo Controlled Trial.

A randomized placebo controlled trial evaluating the effect of the recently recommended high doses of cholecalciferol (3000 IU/day) on mineral metabolism, blood pressure and pulse wave analysis in healthy individuals.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Roskilde, Denmark, 4000
        • Roskilde Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • > 18 years old
  • p 25OH vitaminD<50nmol/l
  • signed informed consent

Exclusion Criteria:

  • receiving antihypertensive or antidiabetic treatment
  • sarcoidoses
  • history of kidney stones
  • receiving 1-alfa-hydroxylated vitamin D treatment
  • plasma creatinin > 120 micromol/l
  • ionised calcium > 1,5 mmol/l
  • treatment with calcimimetics
  • active malignancy
  • intestinal malabsorption
  • active pancreatitis
  • former hospitalisation due to alcoholic related disease
  • using euphoriant drugs
  • pregnancy or risk of being pregnant or lactating women
  • Known allergy to cholecalciferol capsules

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
Empty capsules, 3 capsules per day for 16 weeks
Active Comparator: cholecalciferol
3000 IU cholecalciferol per day for 16 weeks
Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
Other Names:
  • D3-Vitamin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
urinary calcium excretion
Time Frame: before and after 16 weeks of intervention
before and after 16 weeks of intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
25 hydroxyvitamin D
Time Frame: before and after 16 weeks og treatment
before and after 16 weeks og treatment
1,25 dihydroxyvitamin D
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
urinary creatinin
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
urinary protein
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
urinary phosphorous
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
p-FGF23
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
blood pressure
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
pulse wave velocity
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
augmentation index
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
central blood pressure
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
p-phosphate
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
ionised p-calcium
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
p-iPTH
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment
alkalic phosphatase
Time Frame: before and after 16 weeks of treatment
before and after 16 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ditte Hansen, MD, Zealand University Hospital
  • Principal Investigator: Niels Erik Frandsen, MD, Zealand University Hospital
  • Principal Investigator: Knud Rasmussen, DmSci, Zealand University Hospital
  • Principal Investigator: Lisbet Brandi, DmSci, Zealand University Hospital
  • Principal Investigator: Hans Christian Hoeck, DmSci, Center for Clinical and Basic Research

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2009

Primary Completion (Actual)

June 1, 2011

Study Completion (Actual)

June 1, 2011

Study Registration Dates

First Submitted

August 3, 2009

First Submitted That Met QC Criteria

August 4, 2009

First Posted (Estimate)

August 6, 2009

Study Record Updates

Last Update Posted (Estimate)

August 24, 2011

Last Update Submitted That Met QC Criteria

August 23, 2011

Last Verified

August 1, 2011

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe